Source:http://linkedlifedata.com/resource/pubmed/id/10705307
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2000-4-5
|
| pubmed:abstractText |
IL-15 shares several biological activities with IL-2 and uses the b and g chain of the IL-2 receptor. In addition to its T-cell stimulating capacity, IL-15 exhibits regulatory properties on macrophage proinflammatory cytokine release. IL-15 is released by non-lymphoid cells, e.g. muscle cells, fibroblasts and monocytes/macrophages. In many lung diseases alveolar macrophages (AM) are activated and release pro- inflammatory cytokines. We asked whether IL-15 is released ex vivo by AM and peripheral blood mononuclear cells (PBMC) from patients with inactive sarcoidosis (PSi), active sarcoidosis (PSa), tuberculosis (TB), hypersensitivity pneumonitis (HSP), cryptogenic fibrosing alveolitis (CFA) and pneumonia (PN). Additionally, we examined the kinetics of the IL-15 release of these cells. During 24 hours of culture, AM from controls (CO) released 3.8 +/- 1.9 pg/ml (mean +/- SD) of IL-15, which was significantly lower than in most of the patient groups (PSa: 8.7 +/- 3.9 pg/ml, TB: 8.4 +/- 1.9 pg/ml, CFA: 5.7 +/- 1.5 pg/ml, and PN: 7. 8 +/- 2.6 pg/ml) except PSi (4.0 +/- 2.6 pg/ml) and HSP (9.3 +/- 9.5 pg/ml). PBMC from patients with PSa released significantly more IL-15 than PBMC from CO (10.8 +/- 8.9 pg/ml versus 6.9 +/- 2.2 pg/ml) whereas PBMC IL-15 release of the other groups did not differ from CO (TB: 5.7 +/- 1.4 pg/ml; CFA: 4.6 +/- 1.6 pg/ml; HSP: 4.9 +/- 3.8 pg/ml). Kinetic studies revealed a minor peak after 5 hours and a major peak from 12 hours to 35 hours for AM and PBMC. In summary, AM from all patient groups but the PSi and the HSP group released increased levels of IL-15, although the total amount of this cytokine is very low.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1148-5493
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
11
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
105-12
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10705307-Alveolitis, Extrinsic Allergic,
pubmed-meshheading:10705307-Bronchoalveolar Lavage Fluid,
pubmed-meshheading:10705307-Cells, Cultured,
pubmed-meshheading:10705307-Eosinophils,
pubmed-meshheading:10705307-Humans,
pubmed-meshheading:10705307-Interleukin-15,
pubmed-meshheading:10705307-Leukocytes, Mononuclear,
pubmed-meshheading:10705307-Lung Diseases,
pubmed-meshheading:10705307-Lymphocytes,
pubmed-meshheading:10705307-Macrophages, Alveolar,
pubmed-meshheading:10705307-Neutrophils,
pubmed-meshheading:10705307-Pneumonia,
pubmed-meshheading:10705307-Pulmonary Fibrosis,
pubmed-meshheading:10705307-Sarcoidosis,
pubmed-meshheading:10705307-Tuberculosis, Pulmonary
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
In vitro release of interleukin-15 by broncho-alveolar lavage cells and peripheral blood mononuclear cells from patients with different lung diseases.
|
| pubmed:affiliation |
Research Centre Borstel, Medical Hospital, Parkallee 35, 23845 Borstel, Germany. gzissel@fz-borstel.de
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|